Page 4 - Lumiradx Covid News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Lumiradx covid. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Lumiradx Covid Today - Breaking & Trending Today

LumiraDx (NASDAQ:LMDX) Price Target Cut to $0.85 by Analysts at The Goldman Sachs Group

LumiraDx (NASDAQ:LMDX – Get Rating) had its target price cut by The Goldman Sachs Group from $1.20 to $0.85 in a research note released on Wednesday, Benzinga reports. They currently have a neutral rating on the stock. Separately, Raymond James dropped their price target on LumiraDx from $3.50 to $2.00 and set an outperform rating […] ....

Hyman Charles , Raymond James , Boothbay Fund Management , Goldman Sachs Group , Virtu Financial , Citadel Advisors , Get Rating , Lumiradx Daily , Nasdaq Lmdx , Lower Price Target , The Goldman Sachs Group Inc ,

China Life Insurance (NYSE:LFCHY) Receives New Coverage from Analysts at StockNews.com

LumiraDx (NASDAQ:LMDX – Get Rating) had its price target reduced by The Goldman Sachs Group from $1.20 to $0.85 in a research report released on Wednesday, Benzinga reports. They currently have a neutral rating on the stock. Separately, Raymond James cut their price target on shares of LumiraDx from $3.50 to $2.00 and set an […] ....

Raymond James , Hyman Charles , Boothbay Fund Management , Citadel Advisors , Goldman Sachs Group , Virtu Financial , Lumiradx Company Profile , Get Rating , Lumiradx Daily , Nasdaq Lmdx , Lower Price Target , The Goldman Sachs Group Inc ,

Raymond James Cuts LumiraDx (NASDAQ:LMDX) Price Target to $2.00

LumiraDx (NASDAQ:LMDX – Get Rating) had its target price cut by Raymond James from $3.50 to $2.00 in a research note issued to investors on Wednesday morning, Benzinga reports. They currently have an outperform rating on the stock. Separately, The Goldman Sachs Group initiated coverage on shares of LumiraDx in a research note on Monday, […] ....

Raymond James , Hyman Charles , Citadel Advisors , Boothbay Fund Management , Lumiradx Company Profile , Goldman Sachs Group , Virtu Financial , Get Rating , Lumiradx Daily , Nasdaq Lmdx , Lower Price Target ,

LumiraDx Inc: LumiraDx Announces Commercial Shipment of its Point of Care NT-proBNP Test in Europe, Supporting Heart Health Checks in UK

Run on the highly portable LumiraDx Platform, the LumiraDx NT-proBNP test is a quantitative, fingerstick blood assay designed for near-patient testing with lab-comparable results in 12 minutes. It is the ....

United Kingdom , City Of , Ron Zwanziger , Exchange Commission , Lumiradx Limited Nasdaq , Lumiradx Platform , Ultra Pool , Heart Matters Bus , Securities Litigation Reform Act , Annual Report , Profi Marcel Torney ,

LumiraDx Inc: Point of Care (POC) Survey Reveals Majority of U.K. Clinicians Endorse Climate Benefits of POC Through Reduction of Carbon Emissions and Anticipate Future Growth of POC Testing to Come from Community Settings

LumiraDx shares these and other findings from its first annual U.K. survey "Point of Care Diagnostics: A Clinicians View"LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) LumiraDx Limited (Nasdaq: LMDX), a next-generation ....

United Kingdom , City Of , Pooja Pathak , Care Networks Pcns , Lumiradx Limited Nasdaq , Vcare Diagnostics , Primary Care Networks , Integrated Care , Lumiradx Chief Product ,